FDA Warning Letter on Compounded GLP-1 Ads: Why a Disclaimer Will Not Protect a Telehealth Platform or Florida Med Spa

FDA never inspected the company. It never pulled a vial or tested a lot. It read a website and scrolled a feed on X, and on October 30, 2026 it sent a Texas telehealth platform a warning letter stating that the compounded semaglutide and tirzepatide it sells are misbranded. The marketing was the violation.

If you sell GLP-1s through a telehealth funnel, run a med spa weight-loss program, or write the copy for either, read this letter as a list of what the agency is checking right now. It also closes the exit most operators count on. FDA said the fine print does not fix a misleading page.

FDA's October 30, 2026 warning letter rested entirely on a review of a telehealth platform's website and its posts on X. No inspection, sampling, or product defect was involved.

Key Takeaways

• FDA cited a telehealth platform for misbranding under 21 U.S.C. § 352(a) and (bb) based only on its website and posts on X.
• A disclaimer that a compounded drug "may not" be FDA-approved does not cure the misleading overall impression created by approval-style headings, FDA said.
• Private-label vial photos and "American made" claims each support a misbranding finding, and FDA checks origin claims against its own drug listing records.
• Shipping a misbranded drug violates 21 U.S.C. § 331(a); with intent to defraud or mislead, 21 U.S.C. § 333(a)(2) makes each count a felony.
• Florida makes knowingly selling a misbranded drug a second-degree felony under section 499.0051(13), punishable by up to 15 years in prison.

What FDA Found Without an Inspection

The letter came from the Office of Compounding Quality and Compliance in FDA's Center for Drug Evaluation and Research. It was issued October 30 and posted November 3, 2026. FDA reviewed the platform's website and its account on X in September. The company offers compounded semaglutide and tirzepatide. It does not compound them.

The second provision is why a company that never touches the drug can receive the letter. FDA then laid out three theories.

• The vial. Product photos on the website and on X showed the platform's own name on the label. FDA said that suggests the platform is the compounder, and it is not.
• The approval claims. The website grouped products under headings including "Well-Studied Compounded Medications" and "FDA-Approved Compounded Medications," the second defined as compounded drugs whose active ingredient has an FDA-approved branded form. The X bio invited users to explore GLP-1s like Ozempic, and a pinned video pitched $78-a-month drugs like Ozempic. FDA's answer: compounded drugs are not FDA-approved, and disclaimers that a preparation "may not itself be FDA-approved" do not cure the misleading overall impression.
• The flag. The same video called the products "American made" and "farm-to-table drugs" and closed on an American flag and confetti. FDA checked its own records, found no drug listing for semaglutide or tirzepatide active ingredient for compounding that names a registered U.S. manufacturer, and concluded the claim concealed a foreign source.

Product photos showed the platform's own name on the label. FDA said that suggests the platform is the compounder, and it is not.

The company had 15 working days to answer at compoundinginspections@fda.hhs.gov. FDA listed what a response may include: the identity of each entity that produces the drugs offered on the site, a representative sample of labeling, and proof that the claims were removed or corrected. A footnote told the company to reassess its advertising on every platform, including television and social media.

What the Government Is Building

FDA said it had sent thousands of letters in six months, more than in the preceding decade, and the March letters already targeted telehealth-branded products that imply the platform is the compounder.

What is new is the evidence. Based on a full-text search of FDA's posted letters, this appears to be the first in the telehealth GLP-1 series built on social media posts, the first to address disclaimers by name, and the first to test an origin claim against the registration and listing data FDA collects under 21 U.S.C. § 360. None of that requires an inspector. A reviewer with a browser and the agency's own databases can build a letter like this without leaving the office, and FDA has shown it will send them by the dozen.

The response request matters as much as the findings. Once a platform names the pharmacies behind its products, attention moves to those pharmacies, their 503A compounding pharmacy records, and the prescribers whose orders filled the vials. We covered the prescriber side in our post on templated significant difference prescriptions. Med spas sit in the same chain. A med spa that puts its logo on a vial of compounded semaglutide, posts "FDA-approved" on Instagram, or advertises an American-made product is running the copy FDA just cited, and copy like that is where a telehealth fraud investigation often starts.

Once a platform names the pharmacies behind its products, attention moves to those pharmacies, their 503A records, and the prescribers whose orders filled the vials. Med spas sit in the same chain.

Florida and Federal Exposure

Start with Florida, because its statute is harsher. The Florida Drug and Cosmetic Act prohibits selling a misbranded drug and disseminating any false or misleading drug advertisement. A violation is a second-degree misdemeanor under section 499.0051(11). Knowingly selling or offering a misbranded drug is a second-degree felony under section 499.0051(13), punishable by up to 15 years under section 775.082. Florida's telehealth statute, section 456.47, requires out-of-state practitioners to register before treating Florida patients.

The federal track starts with 21 U.S.C. § 331. Section 331(a) bars introducing a misbranded drug into interstate commerce. Section 331(c), which the letter flags, reaches anyone who receives a misbranded drug and delivers it for pay: the platform, the pharmacy, and the med spa that resells. Under 21 U.S.C. § 333(a)(1), a violation is a misdemeanor with no intent requirement, and United States v. Park allows conviction of a responsible corporate officer who had the authority to prevent it. With intent to defraud or mislead, section 333(a)(2) makes each count a felony carrying up to three years. A warning letter is the government's best evidence of that intent, as we explained in A Warning Letter Is Evidence.

Prosecutors rarely stop at the FDCA. Telling a patient that a compounded drug is FDA-approved is a lie about what the patient is buying, and that supports wire fraud under 18 U.S.C. § 1343, the same move we have seen in peptide marketing cases. After Kousisis v. United States, the government does not need to prove the patient suffered a financial loss, only that a material misrepresentation induced the purchase. "The drug worked" is not a defense to that theory. When an agency, a platform, and a pharmacy shared the copy, expect conspiracy under 18 U.S.C. § 371.

Venue follows the shipment. Under 18 U.S.C. § 3237(a), an offense involving interstate transportation can be prosecuted in any district the shipment moves into, so a Texas platform mailing vials to Boca Raton can be charged in the Southern District of Florida. At sentencing, the misbranding guideline, §2N2.1 in the Guidelines Manual, cross-references the fraud guideline when the offense involved fraud, and the government will argue that every subscription dollar is loss.

Mistakes That Turn a Marketing Problem Into a Criminal Case

• Handing the response to the marketing team. The response goes into FDA's file and, if the matter escalates, into a prosecutor's. Bring in a white collar defense attorney before it goes out.
• Deleting posts without preserving them. Fix the content, but keep a forensic copy of what ran and when. Wiping a feed after a warning letter invites an obstruction theory under 18 U.S.C. § 1519, and archive services have usually kept a copy already.
• Trusting the disclaimer. FDA just said it does not work. The test is the overall impression, and a heading that says "FDA-Approved" beats a footnote that says "may not."
• Assuming a letter to someone else means nothing to you. These letters arrive in waves, and the copy often comes from the same agencies and templates. If your page reads like the one FDA cited, you are in the sample.
• Talking to investigators alone. A friendly call from FDA, or from an agent working an FDA OCI investigation, about how the program works is an interview. Answer it through counsel.

A Strategic Defense Approach

Start with a privileged audit, directed by counsel, of everything the public can see: the website, every social account, affiliate and influencer posts, product photos, and the pharmacy labels. Look for the three things this letter names. Vial images that hide who compounded the drug. Any word that sounds like FDA approval or sameness with Ozempic, Wegovy, Mounjaro, or Zepbound. Any claim about where the drug comes from.

Have a GLP-1 compliance attorney review new copy before it runs, not after a letter arrives.

An FDA warning letter response has two readers: the compliance officer at FDA and a future Assistant U.S. Attorney.

If a letter has already arrived, the FDA warning letter response has two readers: the compliance officer at FDA and a future Assistant U.S. Attorney. It should be accurate, specific about corrective action, and careful about anything that reads as an admission of intent. If the matter has moved to a federal grand jury subpoena or an FDA OCI investigation, the goal shifts to pre-charge negotiation with the prosecutor and, where the facts allow, to avoid indictment altogether. GLP-1 compounding defense is federal investigation defense, and it is usually won or lost before charges are filed.

Why Timing Matters Now

A warning letter starts a clock. Every ad the company runs after receipt is conduct with notice, and prosecutors will argue that a published letter puts the rest of the industry on notice as well. That second argument is weaker, but it gets made, and it gets stronger with each wave.

Old content is not safe. The general federal limitations period is five years under 18 U.S.C. § 3282, and archived copies of a website make old copy easy to prove. A platform or med spa that ran approval-style headings in 2024 still has those pages in the record.

If you are already under federal investigation, or a letter, subpoena, or agent's call has reached you, the next two weeks will shape the case more than anything that happens after an indictment.

Common Questions

Received an FDA Warning Letter Over GLP-1 Marketing?

If you run a telehealth platform, compounding pharmacy, or med spa that sells compounded semaglutide or tirzepatide, the questions are what your marketing says, what your labels show, and who else has read them. AMC Defense Law is a federal criminal defense firm in Boca Raton that represents clients in FDA warning letter responses, FDA and DOJ investigations, and federal prosecutions involving compounded drugs, in the Southern and Middle Districts of Florida and nationwide.

Consultations are confidential. Call 561-542-5494, email amc@amcdefenselaw.com, or request a confidential consultation.

If you or your loved ones have been arrested or are under federal investigation, call Aaron M. Cohen, 24 hours a day to get help.

AMC Defense Law audits GLP-1 marketing under privilege, prepares FDA warning letter responses for both of their readers, and works to resolve investigations before charges are filed.